Anti-adalimumab antibodies in juvenile idiopathic arthritis: frequent association with loss of response

被引：30

作者：

Skrabl-Baumgartner, A. ^{[1
]}

Erwa, W. ^{[2
]}

Muntean, W. ^{[1
]}

Jahnel, J. ^{[1
]}

机构：

[1] Med Univ Graz, Dept Paediat & Adolescent Med, Auenbruggerpl 34-2, A-8036 Graz, Austria

[2] Med Univ Graz, Inst Med & Chem Lab Diagnost, A-8036 Graz, Austria

来源：

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY | 2015年 / 44卷 / 05期

关键词：

DISEASE-ACTIVITY SCORE; RHEUMATOID-ARTHRITIS; PEDIATRIC-PATIENTS; IMMUNOGENICITY; METHOTREXATE; EFFICACY; AGENTS;

D O I：

10.3109/03009742.2015.1022213

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives: We aimed to determine how loss of response (LOR) to adalimumab (ADA) in juvenile idiopathic arthritis (JIA) may be related to anti-ADA antibodies (AAA). Method: AAA and ADA levels were measured in 23 consecutive patients with JIA responding significantly to treatment with ADA. Results: Six out of 23 (26%) patients developed AAA and had low ADA levels. Five out of six AAA-positive patients experienced LOR. In these patients use of concomitant methotrexate (MTX) was significantly lower. Conclusions: The occurrence of AAA is a frequent event associated with LOR. Monitoring of AAA and serum ADA levels should be considered in JIA patients under ADA therapy.

引用

页码：359 / 362

页数：4